Kornimate/medical-research-clean huggingface dataset:
effect of abdominal massage versus visceral manipulation on constipation

Conditions: Constipation Chronic Idiopathic

Summary: the study compares the effect of abdominal massage vs. visceral manipulation on constipation status and quality of life in adults. chronic idiopathic constipation (cic) is considered a common functional bowel disorder characterized by difficult, infrequent, and/or incomplete defecation. it has a great impact on the quality of life and on the healthcare system and represents an important financial strain .


Eligibility criteria:
inclusion criteria: * patients of both sex with age ranges (20-40) years old. * having a diagnosis of functional constipation according to rome iv criteria onset of constipation symptoms from 6-12 months . * having body mass index 18.5-29.9 kg/m2 , waist height ratio \</=0.5 * subjects bothered by their constipation exclusion criteria: * pregnancy. * having comorbidities (chronic pelvic pain, neurological (parkinson's, multiple sclerosis, spinal cord lesion, etc.), metabolic / endocrine (diabetes mellitus, hypercalcemia, hypothyroid, etc.), cardiorespiratory diseases * health problems which may prevent standing from sitting, walking (orthopedic, neurological, cardiorespiratory, etc.) * malignancy, acute inflammation, intestinal tumor * history of gastrointestinal and pelvic surgery or spinal surgery other than cholecystectomy, appendectomy, or hysterectomy * visual, auditory or cognitive problems which may prevent participation to the study. * tumor, presence of skin problems in the application area * presence of laxative use for functional constipation in the last four weeks or patients on laxative therapy. * alarm symptoms (unexplained, more than 10% weight loss in 3 months, hemorrhoids and anal fissures, rectal bleeding, family history of colon cancer)

Keywords: chronic idiopathic constipation abdominal massage visceral manipulation quality of life
study in participants with early-stage or locally advanced human epidermal growth factor receptor (her) 2-positive breast cancer to evaluate treatment with trastuzumab plus (+) pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel

Conditions: Breast Cancer

Summary: this is an asia-pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve participants with early-stage or locally advanced her2-positive breast cancer. the anticipated treatment duration is approximately 17 months.


Eligibility criteria:
inclusion criteria: * histologically confirmed invasive breast carcinoma with a primary tumor size of more than (\>) 2 centimeters (cm) by standard local assessment technique * breast cancer stage at presentation: early-stage (t2-3, n0-1, m0) or locally advanced (t2-3, n2 or n3, m0; t4, any n, m0) * her2-positive breast cancer confirmed by a sponsor-designated central laboratory and defined as 3+ score by immunohistochemistry in \> 10 percent (%) of immunoreactive cells or her2 gene amplification (ratio of her2 gene signals to centromere 17 signals equal to or more than \[\>=\] 2.0) by in situ hybridization * known hormone receptor status (estrogen receptor and/or progesterone receptor) * eastern cooperative oncology group performance status equal to or less than (\<=) 1 * baseline left ventricular ejection fracture \>= 55% measured by echocardiography (preferred) or multiple gated acquisition scan * negative serum pregnancy test exclusion criteria: * stage iv metastatic breast cancer * inflammatory breast cancer * previous anti-cancer therapy or radiotherapy for any malignancy * history of other malignancy within 5 years prior to screening, except for appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or stage i uterine cancer * concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy * major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or from which the participant has not fully recovered * serious cardiac illness or medical condition * other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness * any abnormalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization * sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol * pregnant or lactating
a study to evaluate the long-term safety and efficacy of fenebrutinib in participants previously enrolled in a fenebrutinib chronic spontaneous urticaria (csu) study

Conditions: Urticaria

Summary: this is a phase ii, multicenter, open-label extension (ole) study to evaluate the long-term safety and efficacy of fenebrutinib in participants with chronic spontaneous urticaria (csu) who have completed the treatment period in a fenebrutinib csu parent study. participants may enroll in this ole study at any time after completing the treatment period of the parent study. participants will receive open-label fenebrutinib at a dose of 200 milligram (mg) orally twice a day. treatment may continue until the end of the study.


Eligibility criteria:
inclusion criteria: * ability to comply with the study protocol, in the investigator's judgment * completion of the treatment period as specified in the parent study * acceptable demonstration of tolerance to study drug during the parent study as determined by the investigator or medical monitor * for participants receiving treatment with proton-pump inhibitors (ppis) or h2-receptor antagonists (h2ras), agreement to maintain treatment at a stable dose for the first 12 weeks of the study * for women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs * for men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm exclusion criteria * pregnant or breastfeeding, or intending to become pregnant during the study or within 4 weeks after the final dose of fenebrutinib * treatment with any investigational agent or live/attenuated vaccine in the preceding 6 weeks * any signs or symptoms of infection judged by the investigator to be clinically significant since completing the treatment period of the parent study * any significant changes (e.g., events, changes in medication) occurring after completion of participation in the parent study that, in the investigator's judgment, would increase the risk of adverse events in this ole study
testing the chat program for patients with heart failure

Conditions: HFpEF - Heart Failure With Preserved Ejection Fraction

Summary: the researchers are studying whether an intervention that involves video-based educational content and a health coach is acceptable, feasible, and effective for people with heart failure with preserved ejection fraction (hfpef).

this is a pilot randomized controlled trial of 50 subjects that will compare the chat intervention (video-based educational content and a health coach) with usual care. video-based educational content was developed based on adult learning theory and social cognitive theory. key content areas covered by the videos and health coach will include: hfpef overview, signs and symptoms of hfpef, medication management, physical activity and diet with hfpef, and planning for the future (advance care planning).

Eligibility criteria:
inclusion criteria: 1. male or female ≥ 60 years old 2. documentation of hfpef according to clinical practice guidelines (signs \& symptoms of hf and ejection fraction ≥50%) exclusion criteria: 1. previously referred to hospice care 2. prior completion of advance directives 3. moderate-severe dementia or psychiatric disorder precluding informed consent.

Keywords: hfpef chat conversations helpful for awareness of illness trajectory effectiveness-implementation trial heart failure with preserved ejection fraction
mesenchymal stem cells as a treatment for oral complications of graft-versus-host disease

Conditions: Graft -Versus-host-disease

Summary: graft-versus-host disease (gvhd) is a major complication of allogeneic hematopoietic stem cell transplantation (hsct), and is classified as acute (agvhd) or chronic (cgvhd). agvhd onsets within the first 100 days after transplant or with clinical features including erythema, liver dysfunction and oral mucositis, whilst cgvhd or persistent gvhd occurs in approximately 30-60% of transplant patients who survive their first year . long-term five-year prognosis for cgvhd patients is poor with a 70% mortality rate. cgvhd manifests as an autoimmune-like disease affecting multiple sites, including skin, mouth, eyes, gastrointestinal tract, liver, and joints. the oral cavity is the second most common site to be affected with symptoms in 45-83% of cases. in the mouth a diverse spectrum of clinical features can be found for example mucosal lesions can affect almost any site, salivary gland dysfunction and restricted mouth opening. short-term patients can experience mucosal sensitivity, malnutrition, problems speaking, increased caries risk, xerostomia, oral pain and a diminished quality-of-life. long-term complications include secondary malignancies and perhaps early death. clinical management seeks to alleviate the symptoms and improve quality-of-life but 50% of patients fail front-line systemic steroid therapy. oral cgvhd can be treated with topical high potency corticosteroids and oral rinses, however these treatments are not always effective and carry a risk of systemic absorption. mesenchymal stem/stromal cells (mscs) resident in adult and fetal tissues, such as the bone marrow have the capacity to form bone, cartilage, stroma, muscle and fat, are known to exhibit immunosuppressive and immunoregulatory properties both in vivo and in vitro. msc infusions have been used to treat disorders such as osteogenic imperfecta, cardiovascular disease and to heal large bony defects. indeed, the immunosuppressive capacity of mscs have led to infusions being used as a second-line treatment for gvhd patients, and our group has shown within a phase ii clinical trial, 55% agvhd patients who failed front-line steroid treatment responded to msc infusion these studies are going with cgvhd patients. the goal of this project is to perform a pilot study to determine whether msc injections directly into mucosal lesions in patients with oral cgvhd are able to alleviate the symptoms and facilitate the reparative process.


Eligibility criteria:
inclusion criteria: * chronic graft-versus-host disease and oral manifestations grade 3 exhibiting severe symptoms, according to the nih consensus working group for diagnosis and staging of cgvhd and have failed frontline therapy exclusion criteria: * active malignancy * fulfilling criteria for previously initiated study for treatment of chronic graft-versus-host disease

Keywords: graft-versus-host-disease immune system diseases oral
hyaluronic acid hydro-dissection use in idiopathic carpal tunnel syndrome guided by ultrasonic study

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is the most common compression syndrome in the upper extremities, cts is characterized by typical anatomic changes, the most probable swelling of the median nerve in the proximal part of the ct. local infiltration of corticosteroids easily leads to atrophy of the median nerve, subcutaneous fat, and systematic complications, surgical treatment decision is always taken by the patient who sometimes wants to delay or avoid the surgery because of psychological or medical concerns, it would be interesting if low molecular weight sodium hyaluorinate injection is used as an alternative conservative treatment of cts. this study aims to investigate if, and to what extent, hydro-dissection using 1% lidocain followed by injection of sodium hyaluronate versus 1% lidocain followed by injection of 40 mg of triamcinolone acetonide, under ultrasound guidance.

60 ct patients, blindly divided into two groups. both will underwent median nerve hydro-dissection using 1% lidocain followed by group i injection of sodium hyaluronate and group ii injection of 40 mg of triamcinolone acetonide, under ultrasound guidance. baseline vas pain and nerve conduction study, patient satisfaction, and therapeutic duration, will be determined in 2nd week, 3rd and 6th month after the procedure. us measurements of the median nerve cross-sectional area (csa) in the ct inlet will be compared pre and post procedure in 6th month and use ncs results as the gold standard diagnostic test.

Eligibility criteria:
inclusion criteria: * patients with mild or moderate carpal tunnel diagnosed by nerve conduction study exclusion criteria: * secondary carpal tunnel to any other disease and peripheral neuropathy patients

Keywords: hydrodissection sodium hyaluorinate
relation between aldosterone and cardiac remodeling after myocardial infarction

Conditions: Myocardial Infarction

Summary: this study aims to determine whether aldosterone blood levels are predictive of cardiac remodeling at 6 months following myocardial infarction with st elevation (stemi), independently of conventional predictive factors (size of myocardial infarction, age, hypertension, etc.) in revascularized patients during the acute phase of mi.

after myocardial infarction, the evolution toward cardiac failure is generally linked to a progressive worsening of cardiac dysfunction and remodeling. cardiac remodeling is largely the consequence of myocardial injury due to myocardial infarction, although other parameters including age, arterial hypertension, etc. may also represent important predictors. aldosterone blood levels measured within the first hours of admission for myocardial infarction is associated with increased rates of adverse outcomes. aldosterone acts on wound healing and fibrosis processes in the myocardium as well as on systemic volemia.

Eligibility criteria:
inclusion criteria: * man or woman hospitalized for a first myocardial infarction with known shift of the segment st revascularized in acute phase by primary angioplasty and dated less than 4 days * patient presenting a stable clinical state * patient presenting a regular sinusal cardiac rhythm * patient having an age ≥ 18 years exclusion criteria: * counter-indication with examination mri * severe claustrophobia * antecedent of over-sensitiveness to gadolinium salts * nonischaemic cardiopathy * cardiac surgery planed in the 6 months * women into old to procreate without effective contraception

Keywords: aldosterone myocardial infarction cardiac remodeling
evaluation of kidney damage using ngal measurements

Conditions: Prostatectomy; Neutrophil Gelatinase-Associated Lipocalin; Kidney Function Tests

Summary: the main objective of this study is to evaluate whether blood ngal measurement provides superiority over scr and bun tests in early diagnosis for assessing renal function in patients undergoing robotic urological surgery.

the main objective of this study is to evaluate whether blood ngal measurement provides superiority over scr and bun tests in early diagnosis for assessing renal function in patients undergoing robotic urological surgery. the secondary objective of the study is to evaluate the relationship between aki development and monitored parameters such as age, bmi, comorbidities, asa, oab (overactive bladder), mean arterial pressure, intraabdominal pressure, surgical duration, urea and creatinine levels. after obtaining ethical approval from the ministry of health ankara city hospital oncology operating room, a total of 55 patients between the ages of 18-80, asa 1-3, who will undergo general anesthesia under elective conditions will be included in this prospective observational study. during the preoperative period, patients will be evaluated and provided with written informed consent. before being taken to the operating room, patients' age, gender, weight, height, body mass index (bmi), comorbidities, regular medication use, asa classification, hemodynamic values and laboratory values will be recorded in the waiting area. once in the operating room, patients will be monitored according to the standard working protocol of the anesthesia clinic including non-invasive arterial blood pressure monitoring, 3 or 5-channel ecg and pulse oximetry. additionally, standard preoperative and postoperative biochemical profiles (including hemogram) and urinary ngal levels will be measured. during the perioperative period, routine hemodynamic parameters such as heart rate (hr) (beats per minute), systolic arterial blood pressure (sab) (mmhg), diastolic arterial blood pressure (dab) (mmhg), mean arterial blood pressure (oab)(mmhg), peripheral oxygen saturation(spo2) as well as postoperative laboratory values will be recorded. blood samples for ngal measurements will be collected at preoperative and perioperative hours 2nd and 6th. creatinine clearance calculation,hourly urine output; which are commonly used markers to evaluate acute kidney injury(aki) along with standard laboratory parameters,and other complications related to aki management ,will also be recorded.

Eligibility criteria:
inclusion criteria: * a total of 55 patients, with asa scores 1-2-3, aged between 18 and 80 years, will be included in the study conducted at the robotic surgery operating room of ankara city hospital, ministry of health, turkey. exclusion criteria: -1. individuals who do not have the ability to read, understand, or sign the consent form. 2. individuals with diagnosed renal disease. 3. patients who do not wish to participate in the study. 4. patients classified as asa-3 or higher.

Keywords: robotic surgery neutrophil gelatinase-associated lipocalin acute kidney injury
thermosensitive gels for the vaginal delivery of sildenafil citrate

Conditions: Infertility

Summary: the aim of this study was to develop and characterize in situ thermosensitive gels for the vaginal administration of sildenafil as a potential treatment of the endometrial thinning that occurs as a result of the use of clomiphene citrate in induction of ovulation in women with world health organization type ii eu gonadotrophic anovulation.


Eligibility criteria:
inclusion criteria: * women with polycystic ovaries exclusion criteria: * women with other causes of infertility
intrauterine antibiotic infusion in treating chronic endometritis and restoring reproductive dynamics

Conditions: Chronic Endometritis

Summary: chronic endometritis (ce) is related to infertility and entails a challenging management. this study investigates the treatment of off-label intrauterine antibiotic infusion (iai) combined with oral antibiotic administration (oaa), and it assesses respective performance against the gold standard treatment of oaa. data sourced herein reports on treatment efficiency and fertility restoration for both patients aiming to conceive naturally or via in vitro fertilization (ivf).


Eligibility criteria:
inclusion criteria: * positive diagnosis of ce * recurrent pregnancy loss (rpl) or recurrent implantation failure (rif) * no previous live birth * fsh and lh levels -evaluated on day 2 of the menstrual cycle- \<12 iu/ml * amh levels \>1.1ng/ml * progesterone levels -evaluated on day 21 of the menstrual cycle- \> 2 and \<25 ng/ml * 18.5\<bmi\<29.9 * 18\<patients' age\<40 exclusion criteria: * diagnosed endometriosis or other related pelvic inflammatory disorder (pid) * current or previous cancer diagnosis * auto-immune, genetic or reproductive disorders * reproductive history of pregnancy loss due to genetic abnormalities * male factor infertility diagnosis

Keywords: ce treatment infertility oral antibiotic administration intrauterine antibiotic infusion
local infiltration analgesia in bilateral knee arthroplasty - efficacy of subcutaneous wound infiltration with local anesthetic

Conditions: Pain, Postoperative

Summary: local infiltration analgesia is effective in total knee arthroplasty for postoperative pain management, but the efficacy of subcutaneous wound infiltration has not been evaluated. this study aims at evaluating the efficacy of subcutaneous wound infiltration in total knee arthroplasty in 16 patients undergoing bilateral knee arthroplasty.


Eligibility criteria:
inclusion criteria: * total bilateral knee arthroplasty exclusion criteria: * immunological diseases * treatment with opioids or steroids * allergy to any drugs administered
risk evaluation and education for alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to determine the characteristics of those who obtain genetic susceptibility testing for alzheimer's disease with apoe disclosure and to study the psychological and behavioral consequences of providing this information.

advances in genetic research have led to an increased number of testing procedures to determine future risk of disease among at-risk individuals. an increasing number of genes are being identified that confer susceptibility for a given disease rather than inevitably causing it. given that such genes may provide risk information for common diseases (e.g., stroke, depression), there is a growing need to understand how at-risk populations might respond to the option of genetic susceptibility testing. a prominent case in point is alzheimer's disease (ad). participation in this study requires an initial phone call which will elicit some medical and family history information about the participant. a first in-person visit to the clinic will consist of an education session and the administration of some tests to assess memory and thinking skills. this visit will take approximately 2-3 hours. approximately 2 weeks later, participants will return to have their blood drawn for genetic testing. participants will then be randomized to one of two groups. those in the experimental arm will receive information on their risk based on their family history and apoe genotype, while those in the active comparator arm will receive information on their risk for developing alzheimer's disease based on their family history alone. participants will be followed for 1 year following disclosure of results with 2 additional clinic visits.

Eligibility criteria:
inclusion criteria: * adult children of a person with clinically diagnosed and/or autopsy-confirmed alzheimer's disease * 18 years or older exclusion criteria: * current dementia * current untreated depression

Keywords: mild cognitive impairment disease/disorder proneness/risk family genetics genetic counseling genetic marker genetic polymorphism genetic susceptibility
point-of-care assessment of thrombin generation and platelet function in children requiring cardiopulmonary bypass

Conditions: Platelet Function Tests; Thrombin Generation Tests; Perioperative Coagulopathy

Summary: coagulopathy after cardiopulmonary bypass (cpb) is associated with increased morbidity and mortality. clot formation and clot stability are important factors in coagulation and hemostasis. as such platelet dysfunction and impaired thrombin generation play a central role in bleeding after cardiac surgery. the primary objective of this study is to evaluate the relationship between point-of-care determined platelet function and thrombin generation and postoperative bleeding in infants and young children undergoing cardiac surgery with cardiopulmonary bypass adjusting for clinically important confounding factors.


Eligibility criteria:
inclusion criteria: 1. age ≤5 years 2. undergoing cardiac surgery with cardiopulmonary bypass exclusion criteria: 1. non-english speaking parents/care-givers 2. refusal to consent 3. extracorporeal membrane oxygenation (ecmo) or ventricular assist device prior to surgery 4. therapeutic heparin use (unfractionated or low molecular weight) in the immediate preoperative period (\<12 hr) 5. weight \<3 kg